Skip to content
ANAVEX
ANAVEX
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
Search
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
View allAlzheimer's DiseaseAnavex2-73EventsNews ReleasesPDDPIPELINEPressRett Syndrome
Mar312020

Anavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19

March 31, 2020
Mar232020

Anavex Life Sciences to Webcast 2020 Annual Meeting of Shareholders

March 23, 2020
Feb242020

Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Multiple Sclerosis (MS)

February 24, 2020
Feb62020

Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results And Provides Clinical Study Updates

February 6, 2020
Feb32020

Anavex Life Sciences Announces Fast Track Designation Granted by U.S. FDA for ANAVEX®2-73 (blarcamesine) Clinical Development Program for the Treatment of Rett Syndrome

February 3, 2020
Jan302020

Anavex Life Sciences to Announce Fiscal 2020 First Quarter Financial Results on Thursday, February 6th, 2020

January 30, 2020
Jan272020

Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s Disease Dementia (PDD) Clinical Trial

January 27, 2020
Jan82020

Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrome and Multiple Sclerosis

January 8, 2020
Dec162019

Anavex Life Sciences Reports Fiscal Year 2019 Financial Results  And Provides Clinical Study Updates

December 16, 2019
Dec102019

Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019

December 10, 2019
Dec42019

Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer’s Disease (CTAD) 2019 Conference

December 4, 2019
Nov142019

Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome

November 14, 2019
12345…
67891011121314151617181920212223242526272829303132333435363738394041
42

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top